Skip to main content

Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast

Abstract

Purpose

The purpose of this study was to investigate the correlation of primary tumor FDG uptake to clinicopathological prognostic factors in invasive ductal carcinoma of the breast.

Methods

We retrospectively reviewed 136 of 215 female patients with pathologically proven invasive ductal breast cancer from January 2008 to December 2011 who underwent F-18 FDG PET/CT for initial staging and follow-up after curative treatment with analysis of estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (HER2). The maximum standardized uptake value (SUVmax) of the primary breast tumor was measured and compared with hormonal receptor and HER2 overexpression status.

Results

The high SUVmax of primary breast tumors is significantly correlated with the clinicopathological factors: tumor size, histologic grade, TNM stage, negativity of ER, negativity of PR, HER2 overexpression and triple negativity. The recurrent group with non-triple negative cancer had a higher SUVmax compared with the non-recurrent group, though no significant difference in FDG uptake was noted between the recurrence and non-recurrent groups in subjects with triple-negative cancer. Lymph node involvement was the independent risk factor for cancer recurrence in the multivariate analysis.

Conclusions

In conclusion, high FDG uptake in primary breast tumors is significantly correlated with clinicopathological factors, such as tumor size, histologic grade, TNM stage, negativity of the hormonal receptor, HER2 overexpression and triple negativity. Therefore, FDG PET/CT is a helpful prognostic tool to direct the further management of patients with breast cancer.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Jung KW, Park S, Won YJ, Kong HJ, Lee JY, Park EC, et al. Prediction of cancer incidence and mortality in Korea, 2011. Cancer Res Treat. 2011;43:12–8.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB, Jung KH, et al. Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J Breast Cancer. 2012;15:197–202.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Yeo JS, Lee DS, Kang KW, Noh DY, Chung JK, Lee MC. Differential diagnosis of breast mass and staging of breast cancer using F-18-FDG PET. Nucl Med Mol Imaging. 1999;33:502–11.

    Google Scholar 

  4. Tantiwongkosi B, Yu F, Kanard A, Miller FR. Role of (18) F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. World J Radiol. 2014;6:177–91.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol. 2014;202:1316–29.

    Article  PubMed  Google Scholar 

  6. Ian JR, Fiona H, Malcolm RK. FDG-PETCT in the staging of localregional metastases in breast cancer. Breast. 2011;20:491–4.

    Article  Google Scholar 

  7. Yoon JK. Clinical application of 18 F-FDG PET in breast cancer. Nucl Med Mol Imaging. 2008;42(Suppl):76–90.

    Google Scholar 

  8. Song BI, Hong CM, Lee HJ, Kang SM, Jeong SY, Kim HW, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45:117–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Kim JH, Yoo SW, Kang SR, Cho SG, Oh JR, Chong AR, et al. Prognostic significance of metabolic tumor volume measured by 18 F-FDG PET/CT in operable primary breast cancer. Nucl Med Mol Imaging. 2012;46:278–85.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A, editors. AJCC cancer staging manual. 7th ed. New York: NY, Springer; 2010. p. 347–69.

    Google Scholar 

  11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol. 1991;19:403–10.

    Article  CAS  Google Scholar 

  12. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ. American society of clinical oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.

    Article  CAS  PubMed  Google Scholar 

  13. Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess. 2010;14:1–103.

    Article  CAS  Google Scholar 

  14. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern cooperative oncology group companion study, EST 4189. J Clin Oncol. 2000;18:2059–69.

    CAS  PubMed  Google Scholar 

  15. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8.

    Article  PubMed  Google Scholar 

  16. Wang CL, MacDonald LR, Rogers JV, Aravkin A, Haseley DR, Beatty JD. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18 F-FDG. AJR Am J Roentgenol. 2011;197:247–55.

    Article  Google Scholar 

  17. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and ER+, PR+, HER2- breast carcinoma using quantitative F-18 FDG PET imaging parameters. Cancer. 2008;112:995–1000.

    Article  CAS  PubMed  Google Scholar 

  18. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18 F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.

    Article  PubMed  Google Scholar 

  19. Kim BS, Sung SH. Usefulness of 18 F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 2012;26:175–83.

    Article  CAS  PubMed  Google Scholar 

  20. Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618–27.

    Article  PubMed  Google Scholar 

  21. Koolen BB, Vrancken Peeters MJ, Wesseling J, Lips EH, Vogel WV, Aukema TS, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1830–8.

    Article  CAS  PubMed  Google Scholar 

  22. Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18 F] FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915–24.

    Article  CAS  PubMed  Google Scholar 

  23. Kong EJ, Chun KA, Cho IH, Lee SJ. 18 F-FDG PET/CT with contrast enhancement for evaluation of axillary lymph node involvement in T1 breast cancer. Nucl Med Mol Imaging. 2010;44:170–6.

    Article  PubMed Central  PubMed  Google Scholar 

  24. David G, Sylvie G, Jean-Luc M, Raphael P, Marc E, Jacqueline L, et al. Correlation of high 18 F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.

    Article  Google Scholar 

  25. Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15:588–93.

    Article  PubMed  Google Scholar 

  26. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18 F-fluorodeoxyglucose positron emission tomography /computed tomography fusion imaging (18 F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250–8.

    Article  PubMed  Google Scholar 

  27. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652–7.

    Article  PubMed  Google Scholar 

  28. Rebecca D, Maureen T, Kathleen P, Wedad H, Harriet K, Carol S, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.

    Article  Google Scholar 

  29. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–8.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Conflict of Interest

Il Jo, Seok Kil Zeon, Sung Hoon Kim, Hae Won Kim, Sun Hee Kang and Su Jin Kim declare that they have no conflicts of interest.

Ethics Statement

This study was approved by Institutional Review Board of Keimyung University Dongsan Hospital. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Seok Kil Zeon.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jo, I., Zeon, S.K., Kim, S.H. et al. Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast. Nucl Med Mol Imaging 49, 19–25 (2015). https://doi.org/10.1007/s13139-014-0296-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-014-0296-y

Keywords